Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL versus XYLOCAINE DENTAL WITH EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL versus XYLOCAINE DENTAL WITH EPINEPHRINE.
CARVEDILOL vs XYLOCAINE DENTAL WITH EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
Lidocaine blocks voltage-gated sodium channels (Nav1.5, Nav1.7, Nav1.8) in nerve cell membranes, inhibiting sodium influx and preventing depolarization and conduction of nerve impulses. Epinephrine acts as a local vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing systemic absorption and prolonging anesthetic effect.
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
Dose range: 1.0–5.0 mL of 2% lidocaine with 1:100,000 epinephrine (20–100 mg lidocaine) injected locally. Maximum dose: 7 mg/kg lidocaine, not to exceed 500 mg total. Epinephrine component limits: 0.2 mg per visit (200 mcg). Repeat doses after 2–3 hours based on response.
None Documented
Clinical Note
moderateCarvedilol + Digitoxin
"Carvedilol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateCarvedilol + Deslanoside
"Carvedilol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateCarvedilol + Acetyldigitoxin
"Carvedilol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateCarvedilol + Ouabain
"Carvedilol may increase the bradycardic activities of Ouabain."
None Documented
Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation.
Terminal elimination half-life of lidocaine is approximately 1.5–2 hours in adults, but can be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%.
Lidocaine is primarily metabolized in the liver; less than 10% is excreted unchanged in urine. Metabolites are excreted renally. Biliary/fecal excretion is minimal.
Category C
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist